Update in childhood acute myeloid leukemia: Recent developments in the molecular basis of disease and novel therapies

Jennifer J. Clark, Franklin O. Smith, Robert J. Arceci

Research output: Contribution to journalArticle

Abstract

Childhood acute myeloid leukemia is a heterogeneous group of disorders that remains challenging to treat. There are multiple common genetic alterations in childhood acute myeloid leukemia. These include chromosomal translocations affecting RUNX1 -CBFβ, RARα, and MLL. There are known activating mutations in the genes for the receptor tyrosine kinases FLT3, KIT, and FMS. As these abnormalities are better understood, they are providing important insights into the pathogenesis of disease as well as information about prognosis. Although intensive chemotherapy remains the mainstay of acute myeloid leukemia therapy, long-term cure rates with chemotherapy alone remain approximately 50%, creating an urgent need for better therapies. Multiple avenues are being explored in the design of new treatments for pediatric acute myeloid leukemia. Targeted therapies include targeted antibody therapy; inhibitors of FLT3, KIT, and farnesyltransferase; diphtheria toxin conjugated to the granulocyte-macrophage colony-stimulating factor; and antisense oligonucleotides. Another area of interest is chromatin remodeling and differentiation therapy, including agents such as all-trans retinoic acid, arsenic trioxide, and inhibitors of DNA methylation and histone deacetylation. There are also ongoing trials of antiangiogenesis agents. Another avenue for novel therapies is immunotherapy with agents such as interleukin-2 and tumor vaccines. This article reviews recent advances in understanding of the molecular basis for childhood acute myeloid leukemia and the design of novel therapies for the treatment of childhood acute myeloid leukemia.

Original languageEnglish (US)
Pages (from-to)31-39
Number of pages9
JournalCurrent Opinion in Hematology
Volume10
Issue number1
DOIs
StatePublished - Jan 2003

Fingerprint

Acute Myeloid Leukemia
Therapeutics
Farnesyltranstransferase
Diphtheria Toxin
Drug Therapy
Genetic Translocation
Cancer Vaccines
Chromatin Assembly and Disassembly
Antisense Oligonucleotides
Receptor Protein-Tyrosine Kinases
DNA Methylation
Granulocyte-Macrophage Colony-Stimulating Factor
Tretinoin
Histones
Immunotherapy
Interleukin-2
Pediatrics
Mutation
Antibodies
Genes

ASJC Scopus subject areas

  • Hematology

Cite this

Update in childhood acute myeloid leukemia : Recent developments in the molecular basis of disease and novel therapies. / Clark, Jennifer J.; Smith, Franklin O.; Arceci, Robert J.

In: Current Opinion in Hematology, Vol. 10, No. 1, 01.2003, p. 31-39.

Research output: Contribution to journalArticle

Clark, Jennifer J. ; Smith, Franklin O. ; Arceci, Robert J. / Update in childhood acute myeloid leukemia : Recent developments in the molecular basis of disease and novel therapies. In: Current Opinion in Hematology. 2003 ; Vol. 10, No. 1. pp. 31-39.
@article{ca50d38a4e144b63ba6fe90fc2b54263,
title = "Update in childhood acute myeloid leukemia: Recent developments in the molecular basis of disease and novel therapies",
abstract = "Childhood acute myeloid leukemia is a heterogeneous group of disorders that remains challenging to treat. There are multiple common genetic alterations in childhood acute myeloid leukemia. These include chromosomal translocations affecting RUNX1 -CBFβ, RARα, and MLL. There are known activating mutations in the genes for the receptor tyrosine kinases FLT3, KIT, and FMS. As these abnormalities are better understood, they are providing important insights into the pathogenesis of disease as well as information about prognosis. Although intensive chemotherapy remains the mainstay of acute myeloid leukemia therapy, long-term cure rates with chemotherapy alone remain approximately 50{\%}, creating an urgent need for better therapies. Multiple avenues are being explored in the design of new treatments for pediatric acute myeloid leukemia. Targeted therapies include targeted antibody therapy; inhibitors of FLT3, KIT, and farnesyltransferase; diphtheria toxin conjugated to the granulocyte-macrophage colony-stimulating factor; and antisense oligonucleotides. Another area of interest is chromatin remodeling and differentiation therapy, including agents such as all-trans retinoic acid, arsenic trioxide, and inhibitors of DNA methylation and histone deacetylation. There are also ongoing trials of antiangiogenesis agents. Another avenue for novel therapies is immunotherapy with agents such as interleukin-2 and tumor vaccines. This article reviews recent advances in understanding of the molecular basis for childhood acute myeloid leukemia and the design of novel therapies for the treatment of childhood acute myeloid leukemia.",
author = "Clark, {Jennifer J.} and Smith, {Franklin O.} and Arceci, {Robert J.}",
year = "2003",
month = "1",
doi = "10.1097/00062752-200301000-00006",
language = "English (US)",
volume = "10",
pages = "31--39",
journal = "Current Opinion in Hematology",
issn = "1065-6251",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Update in childhood acute myeloid leukemia

T2 - Recent developments in the molecular basis of disease and novel therapies

AU - Clark, Jennifer J.

AU - Smith, Franklin O.

AU - Arceci, Robert J.

PY - 2003/1

Y1 - 2003/1

N2 - Childhood acute myeloid leukemia is a heterogeneous group of disorders that remains challenging to treat. There are multiple common genetic alterations in childhood acute myeloid leukemia. These include chromosomal translocations affecting RUNX1 -CBFβ, RARα, and MLL. There are known activating mutations in the genes for the receptor tyrosine kinases FLT3, KIT, and FMS. As these abnormalities are better understood, they are providing important insights into the pathogenesis of disease as well as information about prognosis. Although intensive chemotherapy remains the mainstay of acute myeloid leukemia therapy, long-term cure rates with chemotherapy alone remain approximately 50%, creating an urgent need for better therapies. Multiple avenues are being explored in the design of new treatments for pediatric acute myeloid leukemia. Targeted therapies include targeted antibody therapy; inhibitors of FLT3, KIT, and farnesyltransferase; diphtheria toxin conjugated to the granulocyte-macrophage colony-stimulating factor; and antisense oligonucleotides. Another area of interest is chromatin remodeling and differentiation therapy, including agents such as all-trans retinoic acid, arsenic trioxide, and inhibitors of DNA methylation and histone deacetylation. There are also ongoing trials of antiangiogenesis agents. Another avenue for novel therapies is immunotherapy with agents such as interleukin-2 and tumor vaccines. This article reviews recent advances in understanding of the molecular basis for childhood acute myeloid leukemia and the design of novel therapies for the treatment of childhood acute myeloid leukemia.

AB - Childhood acute myeloid leukemia is a heterogeneous group of disorders that remains challenging to treat. There are multiple common genetic alterations in childhood acute myeloid leukemia. These include chromosomal translocations affecting RUNX1 -CBFβ, RARα, and MLL. There are known activating mutations in the genes for the receptor tyrosine kinases FLT3, KIT, and FMS. As these abnormalities are better understood, they are providing important insights into the pathogenesis of disease as well as information about prognosis. Although intensive chemotherapy remains the mainstay of acute myeloid leukemia therapy, long-term cure rates with chemotherapy alone remain approximately 50%, creating an urgent need for better therapies. Multiple avenues are being explored in the design of new treatments for pediatric acute myeloid leukemia. Targeted therapies include targeted antibody therapy; inhibitors of FLT3, KIT, and farnesyltransferase; diphtheria toxin conjugated to the granulocyte-macrophage colony-stimulating factor; and antisense oligonucleotides. Another area of interest is chromatin remodeling and differentiation therapy, including agents such as all-trans retinoic acid, arsenic trioxide, and inhibitors of DNA methylation and histone deacetylation. There are also ongoing trials of antiangiogenesis agents. Another avenue for novel therapies is immunotherapy with agents such as interleukin-2 and tumor vaccines. This article reviews recent advances in understanding of the molecular basis for childhood acute myeloid leukemia and the design of novel therapies for the treatment of childhood acute myeloid leukemia.

UR - http://www.scopus.com/inward/record.url?scp=0037215398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037215398&partnerID=8YFLogxK

U2 - 10.1097/00062752-200301000-00006

DO - 10.1097/00062752-200301000-00006

M3 - Article

C2 - 12483109

AN - SCOPUS:0037215398

VL - 10

SP - 31

EP - 39

JO - Current Opinion in Hematology

JF - Current Opinion in Hematology

SN - 1065-6251

IS - 1

ER -